Table 3. Summary of data including the results of the receptors and p53 immunostains, and Fisher’s Exact tests.
| Diagnosis | n | ER | PR | AR | p53 | ||||
| +n | +% | +n | +% | +n | +% | +n | +% | ||
| EEC | 24 | 23 | 96% | 23 | 96% | 23 | 96% | 3 | 13% |
| NEEC | 28 | 13 | 46% | 10 | 36% | 19 | 68% | 27 | 96% |
| SCA | 13 | 11 | 85% | 8 | 62% | 12 | 92% | 13 | 100% |
| CCCA | 5 | 0 | 0% | 0 | 0% | 3 | 60% | 5 | 100% |
| CS | 4 | 2 | 50% | 2 | 50% | 4 | 100% | 4 | 100% |
| DECA | 5 | 0 | 0% | 0 | 0% | 0 | 0% | 5 | 100% |
| MNCA | 1 | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| Met | 1 | 1 | 100% | 0 | 0% | 1 | 100% | 0 | 0% |
| All | 53 | 37 | 70% | 33 | 62% | 43 | 81% | 30 | 57% |
| 2x2 Contingency Table Values | Fisher’s Exact Test P-Values | ||||||||
| Positive | Negative | ER vs p53 | PR vs p53 | AR vs p53 | |||||
| EEC | ER | 23 | 1 | <0.0001 | |||||
| PR | 23 | 1 | <0.0001 | <0.0001 | |||||
| AR | 23 | 1 | |||||||
| p53 | 3 | 21 | |||||||
| NEEC | ER | 13 | 15 | <0.0001 | |||||
| PR | 10 | 18 | <0.0001 | 0.01 | |||||
| AR | 19 | 9 | |||||||
| p53 | 27 | 1 | |||||||
| Met | ER | 1 | 0 | 1* | |||||
| PR | 0 | 1 | 1 | 1 | |||||
| AR | 1 | 0 | |||||||
| p53 | 0 | 1 | |||||||
| All | ER | 37 | 16 | 0.7 | |||||
| PR | 33 | 20 | 0.2 | 0.01 | |||||
| AR | 43 | 10 | |||||||
| p53 | 30 | 23 | |||||||
ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; +, positive reactions; EEC, endometrial endometrioid cancer, NEEC, non-endometrioid endometrial cancers which include: SCA, serous carcinoma; CCCA, clear cell carcinoma; CS, carcinosarcoma; DECA, dedifferentiated endometrial carcinoma; and MNCA, mesonephric like carcinoma; Met, metastatic carcinoma; p53, aberrant-expression as positive, wild-type as negative
*, although the statistical test did net return any result because of the two zeros, the p-value is assumed as "1" since both sets of data are identical.